Application of targeted proline metabolic enzyme in treatment of endometriosis
By targeting the proline metabolism enzyme inhibitors YG1702 and PYCR1-IN-1, the collagen synthesis pathway is blocked, thus solving the fibrosis problem of endometriosis and achieving a precise treatment effect with low side effects.
CN122075709APending Publication Date: 2026-05-26THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202610494005.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-15
- Publication Date
- 2026-05-26
AI Technical Summary
Technical Problem
Current technologies lack effective molecular targets for targeted therapy of endometriosis, drug treatment has side effects, surgical treatment has a high recurrence rate, the mechanism of fibrosis is not fully understood, and there is a lack of treatment strategies targeting fibrosis.
Method used
The targeted proline metabolism enzyme inhibitors YG1702 and PYCR1-IN-1 block the collagen synthesis pathway and reduce collagen deposition by inhibiting the proline synthesis metabolism enzymes P5CS and PYCR1, thereby achieving the treatment of endometriosis.
Benefits of technology
It significantly inhibits collagen synthesis and fibrosis in ectopic lesions, reduces ectopic lesion growth, and provides a precise treatment option with low side effects.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the technical field of medicines, and particularly relates to application of targeted proline metabolic enzyme in treatment of endometriosis. According to in-vitro experiments and EMS animal model verification, the proline content in ectopic endometrial stromal cells is increased, the expression of proline anabolic enzyme is increased, and fibrosis is obviously activated. The present disclosure creatively reuses a proline metabolic enzyme inhibitor for EMS therapy. The proline metabolic enzyme inhibitor blocks a synthetic pathway from glutamic acid to proline by specifically inhibiting the enzyme activity of a proline metabolic key enzyme, and directly reduces the content of proline in cells. As the proline is the main component amino acid of collagen, after synthesis of the proline is blocked, collagen synthesis of intimal stromal cells and expression of fibrosis markers can be directly inhibited, and finally the treatment effects of inhibiting EMS ectopic lesion fibrosis and reducing ectopic lesion growth are achieved.
Need to check novelty before this filing date? Find Prior Art